Elevated FBXL6 activates both wild-type KRAS and mutant KRAS G12D and drives HCC tumorigenesis via the ERK/mTOR/PRELID2/ROS axis in mice.
Hao-Jun XiongHong-Qiang YuJie ZhangLei FangDi WuXiao-Tong LinChuan-Ming XiePublished in: Military Medical Research (2023)
-induced tumorigenesis, providing a potential therapeutic strategy to treat this aggressive subtype of liver cancer.